Insider buying last 90 days
No open-market insider purchases were filed for G in the last 90 days.
From Form 4 filings, dated to when each was filed.
Genpact's third-quarter results drove this week's move, with revenue rising 7.3% as demand for technology and artificial intelligence services accelerated. The company reported diluted earnings per share of $0.89, up from $0.83 a year earlier, on revenue of $1,385.4 million, with Advanced Technology Solutions net revenue growth of 30% year-over-year. Genpact raised its 2026 guidance for gross margin and adjusted diluted earnings per share, while nine-month operating cash flow decreased to $142.021 million from $526.161 million in 2025, attributed to higher receivables balances.
Shares closed at $42.55, up 0.7%, sitting above both the 50-day average of $36.62 and the 200-day average of $35.39, with the 50-day above the 200-day. The GekkoIndex reads 45.3, placing the stock in the Neutral zone, down 5.3 over five sessions. Price remains 31.5% below Gekko Fair Value of $62.16. One-month and three-month returns stand at 23.7% and 25.3%, with a 52-week range of $26.85 to $48.64.
The next earnings date falls on 4 February 2027, 86 days out and beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality from this point in the calendar has averaged a 2.6% gain over the next 20 trading days across 5 years, rising in 3 of them. Analyst consensus across 8 firms includes 3 buy and 5 hold ratings, with a consensus target of $42.91.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Genpact scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $43.61 is above the 50-day ($37.06) and 200-day ($35.36) averages, and the 50-day is above the 200-day.
See the chart46, Neutral
Reading 46 is in the Neutral zone.
See the GekkoIndex29.6% below
Price is 29.6% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 81 days
Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.
See earnings+1.3% on average
From this point in the calendar, the next 20 trading days averaged +1.3% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Genpact closed at $43.61 on Nov 13, 2026, −4.2% over the past year, inside a 52-week range of $26.85 to $48.64.
Use the left and right arrow keys to read daily values.
Put G on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Genpact works with businesses around the globe, handling back-office and technology tasks so clients can hand off process-heavy work. Customers are found across India, other Asian markets, the Americas, and Europe. The firm has built a strong reputation for managing finance and accounting tasks on behalf of other companies, taking on everything from paying invoices to collecting payments to closing the books each period, while also advising finance chiefs and guiding clients through environmental and social reporting requirements.
Client work is grouped into three areas: one centered on banks, capital markets firms, and insurers; another covering consumer goods, retail, life sciences, and healthcare companies; and a third focused on technology, manufacturing, and services businesses. Genpact also handles procurement and sourcing tasks, supply chain coordination, and after-sales assistance, plus sales support like managing orders, resolving disputes, and setting prices. On the technology side, it manages infrastructure, applications, and databases for clients, and it helps organizations shift how they operate through consulting, digital projects, and data analysis.
The company traces back to 1997 and runs its headquarters out of Hamilton, Bermuda. Investors can find its stock listed on the NYSE under the ticker G.
Genpact’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46, in the Neutral zone, down 0.3 points over five sessions.
Down 0.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 46 | +1.3% | +3.3% | ||
| Accumulation | 279 | +0.2% | +1.5% | ||
| Neutral (current zone) | 322 | +0.1% | −0.2% | ||
| Distribution | 48 | +0.7% | +0.1% | ||
| Selling | 7 | Too few readings yet | |||
Average G share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Genpact trades 29.6% below Gekko Fair Value of $61.92, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Genpact shares are worth, recalculated every trading day.
$61.92
Gekko Fair Value, Nov 14, 2026
29.6% Undervalued
At the end of Aug 2026 the price was 42.8% below the estimate.
No open-market insider purchases were filed for Genpact, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for G in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in G were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Genpact has been buying back its own shares.
From company filings.
Genpact reports on Feb 4, 2027, after the close (81 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 4, 2027
Expected after the close, 81 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.00 est $0.97 | $1.34B est $1.33B | −2.8% |
| May 7, 2026 | $0.98 est $0.92 | $1.30B est $1.29B | −3.7% |
| Feb 5, 2026 | $0.97 est $0.94 | $1.32B est $1.31B | +5.3% |
| Nov 6, 2025 | $0.97 est $0.90 | $1.29B est $1.27B | +14.6% |
| Aug 7, 2025 | $0.88 est $0.85 | $1.25B est $1.26B | +3.2% |
| May 7, 2025 | $0.84 est $0.80 | $1.21B est $1.21B | −15.4% |
| Feb 6, 2025 | $0.91 est $0.86 | $1.25B est $1.23B | +11.2% |
| Nov 7, 2024 | $0.85 est $0.80 | $1.21B est $1.19B | +13.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Genpact is $47.64, +9.2% from the last close, from 8 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 8 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | Mizuho Securities | $44 | +0.9% |
| Nov 9 | Citi | $44 | +0.9% |
| Nov 6 | Robert W. Baird | $48 | +10.1% |
| Nov 6 | Bank of America Securities | $58 | +33.0% |
| Nov 6 | TD Cowen | $50 | +14.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Genpact averaged +1.3% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.7% | 1 of 5 |
| Next 10 trading days | −1.0% | 3 of 5 |
| Next 15 trading days | +0.9% | 3 of 5 |
| Next 20 trading days | +1.3% | 3 of 5 |
| Next 30 trading days | +1.8% | 4 of 5 |
For scale, G’s typical 20-trading-day move in either direction is about 5.3%.
Genpact’s market cap is $7.39B, with a P/E ratio of 12.6 and revenue of $5.34B over the last twelve months.
Coverage of Genpact this week reads positive: 2 positive, 2 neutral and 0 negative headlines.
Genpact’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Accumulation | 0.6% above |
| CTASCintas | Neutral | 22.3% above |
| PYPLPayPal | Neutral | 5.3% above |
| XYZBlock | Neutral | 15.1% above |
| FISVFiserv | Distribution | 38.0% below |
| CPAYCorpay | Distribution | 5.1% below |
A peer links to its own page where one exists.
Genpact’s market cap is $7.39B at the Nov 13, 2026 close of $43.61, with 167.2M shares outstanding. The shares trade on a P/E ratio of 12.6.
The consensus analyst 12-month price target for Genpact is $47.64, +9.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 3 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Genpact is undervalued: the Nov 13, 2026 close of $43.61 is 29.6% below Gekko Fair Value of $61.92. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Genpact is expected to report on Feb 4, 2027, after the market closes (81 days away). Analysts expect earnings of $1.09 per share on revenue of $1.41B. Genpact beat the earnings estimate in 8 of its last 8 reports, moving 8.7% on average across the report.
Genpact’s 52-week high is $48.64 and its 52-week low is $26.85; it closed at $43.61 on Nov 13, 2026, −4.2% over the past year. Over the last five years the shares peaked at $56.76 on Feb 7, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.